DDrare: Database of Drug Development for Rare Diseases

283. 後天性赤芽球癆
［臨床試験数：17，薬物数：36（DrugBank：19），標的遺伝子数：16，標的パスウェイ数：91］

Searched query = "Acquired pure red cell aplasia", "Pure red cell aplasia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = AF37702 Injection; AF37702, Hematide; Alemtuzumab; Anti-thymocyte globulin; Bortezomib; Bortezomib/dexamethasone; Campath; Campath, Chemo and/or TBI Allo SCT; Cyclophosphamide; Cyclophosphamide + pred; Cyclosporine; Cyclosporine A; Cyclosporine combine with mycophenolate mofetil; Daclizumab; Dexamethasone; Filgrastim; Fludarabine; Fludarabine Phosphate; Hematide; Hematide, peginesatide; Leucine; Methylprednisolone; Mycophenolate; Mycophenolate mofetil; Other: Laboratory Biomarker Analysis; Peginesatide; Phosphate; Prednisone; Procedure: Autologous Peripheral Blood Stem Cell Transplantation; Procedure: Peripheral Blood Stem Cell Transplantation; Radiation: Total Body Irradiation; Radiation: Total-Body Irradiation; Rituximab; Sirolimus; Tacrolimus; Trifluoperazine

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00229619 (ClinicalTrials.gov)	September 2005	29/9/2005	Rituximab to Treat Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia	A Pilot Study of Recombinant Humanized Anti- Cluster of Differentiation Antigen 20 (Anti-CD20) Antibody (Rituximab) in Patients With Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia	Anemia, Aplastic;Red-Cell Aplasia, Pure;Anemia, Diamond-Blackfan	Drug: Rituximab	National Heart, Lung, and Blood Institute (NHLBI)	NULL	Completed	2 Years	N/A	All	11	Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00229619
(ClinicalTrials.gov)

September 2005

29/9/2005

Rituximab to Treat Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia

A Pilot Study of Recombinant Humanized Anti- Cluster of Differentiation Antigen 20 (Anti-CD20) Antibody (Rituximab) in Patients With Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia

Anemia, Aplastic;Red-Cell Aplasia, Pure;Anemia, Diamond-Blackfan

Drug: Rituximab

National Heart, Lung, and Blood Institute (NHLBI)

NULL

Completed

2 Years

N/A

All

Phase 2

United States